TIDMSDI
RNS Number : 2174L
Scientific Digital Imaging Plc
08 January 2016
Scientific Digital Imaging plc
("SDI", the "Company" or the "Group")
(AIM: SDI)
UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS TO 31 OCTOBER
2015
The Board of Scientific Digital Imaging plc, the AIM quoted
group focused on scientific and technology products for use in
applications including life sciences, healthcare, astronomy,
consumer manufacturing and art conservation, is pleased to announce
its unaudited interim results for the six months ended 31 October
2015.
Highlights
-- Revenue increased by 15% to GBP3,671,000 (2014: GBP3,188,000)
-- Adjusted operating profit* was GBP189,000 (2014: loss GBP20,000)
-- Operating profit was GBP29,000 (2014: loss GBP207,000)
-- Gross margin increased to 58.0% (2014: 57.6%)
-- New acquisition Sentek Limited ("Sentek") acquired on 28
October 2015. SDI paid GBP2,000,000. The acquisition was funded
initially using existing cash resources and a debt facility, with
the majority of the debt subsequently repaid by raising
GBP2,500,000 in equity after the period end
-- Post period event - settlement following a general meeting of
the successful equity fundraising of GBP2,500,000 (before expenses)
to repay debt from acquiring Sentek, with the balance of net
proceeds to be reinvested in the business
-- Artemis CCD continued to report increased levels of sales and profitability
* Before transaction costs, reorganisation costs and share based
payments
Ken Ford, Chairman of SDI, commented:
"The Board anticipates that the recent acquisition of Sentek
will be earnings enhancing in the first full year of ownership. The
Board expects SDI to continue to make good progress over the
remainder of the financial year as we continue to pursue our
strategy of organic and acquisitive growth."
Enquiries
Scientific Digital Imaging plc 01223 727144
Ken Ford, Chairman
Mike Creedon, CEO
www.scientificdigitalimaging.com
finnCap Ltd 020 7220 0500
Ed Frisby/Simon Hicks - Corporate Finance
Mia Gardner- Corporate Broking
JW Communications 07818 430877
Julia Wilson - Investor & Public Relations
Copies of the interim report are being sent to shareholders and
can also be viewed on the Company's website:
www.scientificdigitalimaging.com
About SDI:
Scientific Digital Imaging plc ("SDI") designs and manufactures
scientific and technology products for use in applications
including life sciences, healthcare, astronomy, consumer
manufacturing and art conservation. SDI plans to continue to grow
through its own technology advancements as well as strategic,
complementary acquisitions.
IMPORTANT NOTICES
No statement in this announcement is intended to be a profit
forecast or estimate and no statement in this announcement should
be interpreted to mean that earnings per share of the Company for
the current or future financial years would necessarily match or
exceed the historical published earnings per share of the
Company.
Interim 2015 highlights
-- Revenue increased by 15% to GBP3,671,000 (2014: GBP3,188,000)
-- Adjusted operating profit* was GBP189,000 (2014: loss GBP20,000)
-- Operating profit was GBP29,000 (2014: loss GBP207,000)
-- Gross margin increased to 58.0% (2014: 57.6%)
-- New acquisition Sentek Limited ("Sentek") acquired on 28
October 2015. SDI paid GBP2,000,000. The acquisition was funded
initially using existing cash resources and a debt facility, with
the majority of the debt subsequently repaid by raising
GBP2,500,000 in equity after the period end
-- Post period event - settlement following a general meeting of
the successful equity fundraising of GBP2,500,000 (before expenses)
to repay debt from acquiring Sentek, with the balance of net
proceeds to be reinvested in the business
-- Artemis CCD continued to report increased levels of sales and profitability
* Before transaction costs, reorganisation costs and share based
payments
Synoptics
Synoptics designs and manufactures special-purpose, innovative
instruments and systems for use mainly in the life science
industry. The Company exploits digital imaging technologies for a
range of disciplines and offers its products through four
brands:
-- Syngene produces equipment for life scientists to image and
analyse electrophoresis gels for DNA and protein analysis
-- Synbiosis produces equipment for microbiologists to automate microbial colony counting
-- Syncroscopy provides systems that apply digital imaging
techniques to microscopy applications, such as life and material
sciences
-- Synoptics Health focuses on imaging techniques within the
hospital and clinical environments using the ProReveal system.
Artemis CCD
Artemis CCD designs and manufactures high sensitivity cameras
for deep sky astronomical and life science imaging under the Atik
brand.
Opus Instruments
Opus designs and manufactures an infrared camera, Osiris, which
is used to examine works of art using infrared camera
technology.
Sentek
Sentek manufactures and sells both reusable and single-use
electrodes for the measurement of pH and conductivity of aqueous
solutions. Applications range from laboratory use to manufacture of
foods, beverages, pharmaceuticals and personal care products.
Chairman's statement
OVERVIEW
In the six-month period ended 31 October 2015, SDI acquired
Sentek. The acquisition was completed on 28 October 2015 and
therefore has very limited effect on the six month period results.
Going forward, we expect that the acquisition of Sentek will be
earnings enhancing in the first full year of ownership.
SDI revenue was GBP3,671,000 in the six months to 31 October
2015 (increased by GBP483,000 relative to revenue of GBP3,188,000
for the six months to 31 October 2014). The increase in revenue
arose from Synoptics and Atik over the six-month period.
The established Atik brand continued to report increased sales
revenue and profitability.
Basic and fully diluted earnings per share were both 0.04p
(2014: basic and fully diluted loss 0.82p).
The Group's cash position reduced by GBP619,000 to GBP257,000
over the period, due to the utilisation of internal funds to
contribute to the purchase of Sentek. After the period end, SDI
raised GBP2,500,000 before expenses through the issue of equity and
borrowed GBP500,000 from its bank, used to repay short-term debt
funding the purchase of Sentek with the remainder increasing the
Group's working capital reserves.
PRODUCT PORTFOLIO
Syngene remains the largest of the Synoptics brands. It has been
continuing to improve its software and hardware, for a number of
its products. We believe that these improvements will be attractive
to our current and potential customers.
During the period, Synbiosis released a new version of ProtoCOL
3, including antibiotic susceptibility testing software. The new
software is stimulating additional interest in ProtoCOL 3;
Synbiosis believes that this will translate into sales growth in
2016. The division is currently developing a new system,
ChromaZona, for antibiotic resistance testing in clinical
laboratories. It is currently undergoing clinical certification as
it will be used for clinical diagnostics and we can then seek to
exploit new large and growing markets including hospital
laboratories.
Synoptics Health has continued to sell ProReveal, a test to
detect proteins on surgical instruments. The absence of an official
limit of acceptable protein contamination on re-usable surgical
instruments was previously a significant barrier to the adoption by
the NHS of ProReveal. In May 2015, the UK Department of Health
(DoH) published new guidelines that define a limit for acceptable
protein contamination on re-usable surgical instruments
(http://www.gov.uk/government/publicatons/
guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group).
We expect the publication of these guidelines to accelerate
adoption of ProReveal for this use. ProReveal is the only available
CE-marked instrument capable of determining quantitatively the
level of protein contamination on instruments. Furthermore, it has
been shown to be sensitive below 50ng of protein and thus fulfils
the DoH requirements for greater sensitivity for neurosurgical
instruments.
Since acquiring Opus Instruments in 2014, Osiris camera sales
have remained steady. The Board believes that it will continue to
make a positive contribution to SDI's trading in 2016.
In the first half of the financial year, Atik reported growth in
sales and profitability. Atik constantly analyses the market and
seeks to develop cutting edge products to attract a wider customer
base. The recently introduced Infinity camera marks a departure
from its existing astro-imaging products which are intended to
collect data that is subsequently processed to a finished picture.
The Infinity is used with a telescope to provide astronomers with
near real time visualisation of faint deep sky objects such as
galaxies and nebulas. The camera is proving particularly popular
with astronomers who had been reluctant to try astro-imaging due to
the steep learning curve, as well as those involved with outreach
projects. We believe that the Infinity camera will help introduce
the Atik brand to a new group of astronomers and provide an easy
entry point to the rewarding astro-imaging hobby market.
(MORE TO FOLLOW) Dow Jones Newswires
January 08, 2016 02:00 ET (07:00 GMT)
SDI's latest acquisition Sentek differs in its business profile
from SDI's other established divisions. Sentek makes and sells
consumables rather than equipment and software, so it has a stream
of repeat business. Sentek's products are electrodes that have a
working life of only six to twelve months and need to be replaced
regularly. Sentek also produces a single-use electrode for
bioprocessing applications, a fast-growing area in pharmaceutical
and biotech companies. The business has been profitable since
incorporation in 1991; it has had a revenue CAGR* over the past
five years of 9% and a five-year profit before tax CAGR of 33%.
ACQUISITIONS
SDI is actively seeking further profitable scientific and
technology based companies to continue its buy and build
strategy.
OUTLOOK
The Board anticipates that the recent acquisition of Sentek will
be earnings enhancing in the first full year of ownership. The
Board expects SDI to continue to make good progress over the
remainder of the financial year as we continue to pursue our
strategy of organic and acquisitive growth.
Ken Ford, Chairman
8 January 2016
* CAGR = compound annual growth rate
Consolidated income statement
Unaudited for the six months ended 31 October 2015
6 months 6 months 12 months
to to to
31 October 31 October 30 April
2015 2014 2015
Unaudited Unaudited Audited
Note GBP'000 GBP'000 GBP'000
---------------------------------- ----- ------------ ------------ ----------
Revenue 3,671 3,188 6,955
----------
Costs of sales (1,541) (1,353) (2,837)
---------------------------------- ----- ------------ ------------ ----------
Gross profit 2,130 1,835 4,118
Administrative expenses (1,941) (1,855) (3,725)
----------
Adjusted operating profit/(loss) 189 (20) 393
Reorganisation costs (17) (51) (200)
Share based payments (4) (5) (8)
Acquisition and fundraising
costs (139) - (126)
Aborted transaction costs - (131) -
---------------------------------- ----- ------------ ------------ ----------
Operating profit/(loss) 29 (207) 59
----------
Net financing expense (16) (20) (36)
---------------------------------- ----- ------------ ------------ ----------
Profit/(loss) before taxation 13 (227) 23
----------
Income tax expense - - 21
---------------------------------- ----- ------------ ------------ ----------
Profit/(loss) for the period 13 (227) 44
---------------------------------- ----- ------------ ------------ ----------
Earnings per share
----------
Basic earnings/(loss) per
share 2 0.04p (0.82p) 0.15p
---------------------------------- ----- ------------ ------------ ----------
Diluted earnings/(loss)
per share 0.04p (0.82p) 0.15p
---------------------------------- ----- ------------ ------------ ----------
Consolidated statement of comprehensive income
Unaudited for the six months ended 31 October 2015
6 months 6 months 12 months
to to to
31 October 31 October 30 April
2015 2014 2015
Unaudited Unaudited Audited
GBP'000 GBP'000 GBP'000
----------------------------------------------- ------------ ------------ ----------
Profit/(loss) for the period 13 (227) 44
----------
Other comprehensive income
Items that will be reclassified subsequently
to profit and loss
----------
Exchange differences on translating
foreign operations - 38 40
----------------------------------------------- ------------ ------------ ----------
Total comprehensive profit/(loss)
for the period 13 (189) 84
----------------------------------------------- ------------ ------------ ----------
Consolidated balance sheet
Unaudited at 31 October 2015
31 October 31 October 30 April
2015 2014 2015
Unaudited Unaudited Audited
Note GBP'000 GBP'000 GBP'000
------------------------------------------- ----- ----------- ----------- ---------
Assets
---------
Non-current assets
---------
Property, plant and equipment 367 379 417
Intangible assets 4,103 2,064 2,012
Deferred tax asset 105 99 105
------------------------------------------- ----- ----------- ----------- ---------
4,575 2,542 2,534
Current assets
Inventories 1,159 1,059 982
Trade and other receivables 1,244 1,344 1,584
Current tax assets - - 5
Cash and cash equivalents 365 316 876
------------------------------------------- ----- ----------- ----------- ---------
2,768 2,719 3,447
------------------------------------------- ----- ----------- ----------- ---------
Total assets 7,343 5,261 5,981
------------------------------------------- ----- ----------- ----------- ---------
Liabilities
---------
Current liabilities
Overdraft 108 - -
---------
Trade and other payables 1,432 1,527 1,452
---------
Provisions for warranty 19 17 18
---------
Borrowings 3 1,343 143 269
---------
Current tax payable - - -
------------------------------------------- ----- ----------- ----------- ---------
2,902 1,687 1,739
---------
Non-current liabilities
---------
Borrowings 3 372 198 156
---------
Trade and other payables 73 138 101
---------
Deferred tax liability 174 169 174
------------------------------------------- ----- ----------- ----------- ---------
619 505 431
------------------------------------------- ----- ----------- ----------- ---------
Total liabilities 3,521 2,192 2.170
------------------------------------------- ----- ----------- ----------- ---------
Net assets 3,822 3,069 3,811
------------------------------------------- ----- ----------- ----------- ---------
Equity
(MORE TO FOLLOW) Dow Jones Newswires
January 08, 2016 02:00 ET (07:00 GMT)
---------
Share capital 329 278 329
Merger reserve 3,030 3,030 3,030
Share premium account 1,472 1,063 1,478
Foreign exchange reserve (72) (71) (69)
Own shares held by Employee Benefit Trust (85) (85) (85)
Other reserves 80 70 73
Retained earnings (932) (1,216) (945)
------------------------------------------- ----- ----------- ----------- ---------
Total equity 3,822 3,069 3,811
------------------------------------------- ----- ----------- ----------- ---------
Consolidated statement of cash flows
Unaudited for the six months ended 31 October 2015
12 months
6 months to 6 months to to
31 October 31 October 30 April
2015 2014 2015
Unaudited Unaudited Audited
GBP'000 GBP'000 GBP'000
---------------------------------------- -------------- ------------ -----------
Operating activities
-----------
Profit/(loss) for the period 13 (227) (44)
Depreciation and amortisation 256 282 571
Finance costs and income 16 20 36
Taxation expense in the income
statement - - (21)
Increase in provisions 1 - 1
Employee share based payments 4 5 8
---------------------------------------- -------------- ------------ -----------
Operating cash flow before movement
in working capital 290 80 639
(Increase)/decrease in inventories (177) 58 135
Changes in trade and other receivables 340 (52) (298)
Changes in trade and other payables (48) 103 (37)
---------------------------------------- -------------- ------------ -----------
Cash generated from operations 405 189 439
Interest paid (16) (20) (26)
Income taxes (received)/paid 5 (35) (4)
---------------------------------------- -------------- ------------ -----------
Cash generated from operating
activities 394 134 409
Cash flows from investing activities
Capital expenditure on fixed
assets (97) (62) (255)
Expenditure on development and
other intangibles (137) (159) (299)
Acquisition of subsidiaries, (2,111) -
net of cash -
Proceeds from sale of property,
plant and equipment 40 - 65
---------------------------------------- -------------- ------------ -----------
Net cash used in investing activities (2,305) (221) (489)
Cash flows from financing activities
Movement in finance leases (13) (12) (33)
Share issue costs (6) - -
Proceeds from share issue - - 466
Share based payment reserve 7 - -
Repayment of borrowings (50) (118) (30)
Other loans 100 - -
Proceeds from bank borrowings 1,253 - -
---------------------------------------- -------------- ------------ -----------
Net cash from/(used in) financing
activities 1,291 (130) 403
---------------------------------------- -------------- ------------ -----------
Net (decrease)/increase in cash
and cash equivalents (620) (217) 323
Cash and cash equivalents, beginning
of period 876 539 539
Foreign currency movements on
cash balances 1 (6) 14
---------------------------------------- -------------- ------------ -----------
Cash and cash equivalents, end
of period 257 316 876
---------------------------------------- -------------- ------------ -----------
Consolidated statement of changes in equity
Unaudited for the six months ended 31 October 2015
6 months to 31 October Own shares
2015 - unaudited Share Merger Share held by Other Foreign Retained
capital reserve premium EBT reserves exchange earnings Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
------------------------- --------- --------- --------- ----------- ---------- ---------- ---------- ---------
Balance at 1 May 2015 329 3,030 1,478 (85) 73 (69) (945) 3,811
Share based payments - - - - 7 - - 7
Fundraising costs - - (6) - - - - (6)
Transactions with owners - - (6) - 7 - - 1
------------------------- --------- --------- --------- ----------- ---------- ---------- ---------- ---------
Profit for the period - - - - - - 13 13
Foreign exchange on
consolidation
of subsidiary - - - - - (3) - (3)
------------------------- --------- --------- --------- ----------- ---------- ---------- ---------- ---------
Total comprehensive
income for
the period - - - - - (3) 13 10
------------------------- --------- --------- --------- ----------- ---------- ---------- ---------- ---------
Balance at 31 October
2015 329 3,030 1,472 (85) 80 (72) (932) 3,822
------------------------- --------- --------- --------- ----------- ---------- ---------- ---------- ---------
6 months to 31 October Own shares
2014 - unaudited Share Merger Share held by Other Foreign Retained
capital reserve premium EBT reserves exchange earnings Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
------------------------- --------- --------- --------- ----------- ---------- ---------- ---------- ---------
Balance at 1 May 2014 278 3,030 1,063 (85) 65 (109) (989) 3,253
Share based payments - - - - 5 - - 5
Transactions with owners - - - - 5 - - 5
------------------------- --------- --------- --------- ----------- ---------- ---------- ---------- ---------
Loss for the period - - - - - - (227) (227)
Foreign exchange on
consolidation
of subsidiary - - - - - 38 - 38
------------------------- --------- --------- --------- ----------- ---------- ---------- ---------- ---------
Total comprehensive
income for
the period - - - - - 38 (227) (189)
------------------------- --------- --------- --------- ----------- ---------- ---------- ---------- ---------
Balance at 31 October
2014 278 3,030 1,063 (85) 70 (71) (1,216) 3,069
------------------------- --------- --------- --------- ----------- ---------- ---------- ---------- ---------
12 months to 30 April Own shares
2015 - audited Share Merger Share held by Other Foreign Retained
capital reserve premium EBT reserves exchange earnings Total
(MORE TO FOLLOW) Dow Jones Newswires
January 08, 2016 02:00 ET (07:00 GMT)
Sdi (LSE:SDI)
Historical Stock Chart
From Apr 2024 to May 2024
Sdi (LSE:SDI)
Historical Stock Chart
From May 2023 to May 2024